Fulminant Lymphocytic Myocarditis Successfully Managed with Intra-Aortic Balloon Pump and Extracorporeal Membrane Oxygenation: A Case Report.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
BACKGROUND Lymphocytic myocarditis (LM) is a rare inflammatory disease of the heart. The clinical presentation of LM varies from mild flu-like symptoms to fulminant myocarditis with cardiogenic shock. Fulminant myocarditis has a poor prognosis and the usual treatment is inotropes with or without ventricular assist devices such as intra-aortic balloon pump (IABP) and venoarterial extracorporeal membrane oxygenation (V-A ECMO). We report the case of fulminant LM with severe cardiogenic shock that was successfully treated with concomitant use of IABP and V-A ECMO. CASE REPORT A 32-year-old woman with no medical history presented to the Emergency Department (ED) with chest pain with irradiation to the left upper limb, worse when supine. The electrocardiogram (ECG) on admission showed sinus rhythm with nonspecific ST-T repolarization abnormalities, and laboratory results showed elevated ultrasensitive troponin and C-reactive protein. Transthoracic echocardiography (TTE) showed left ventricular ejection fraction (LVEF) of 25% and diffuse hypokinesis. On the next day, she developed cardiogenic shock requiring vasoactive drugs, IABP, and V-A ECMO. Pulse therapy with methylprednisolone was started. Endomyocardial biopsy (EMB) revealed acute LM, and intravenous human immunoglobulin was administered. The patient evolved with progressive clinical improvement, being discharged 56 days after admission, with an improvement in the LVEF to 55%. CONCLUSIONS Fulminant LM is a rare and potentially fatal condition that requires immediate intervention. The combination of IABP and V-A ECMO among patients with LM-cardiogenic shock may provide survival benefits.
Identifiants
pubmed: 37908061
pii: 941422
doi: 10.12659/AJCR.941422
pmc: PMC10626596
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e941422Références
Diagnostics (Basel). 2022 Feb 03;12(2):
pubmed: 35204490
J Am Coll Cardiol. 2003 Aug 6;42(3):466-72
pubmed: 12906974
Front Cardiovasc Med. 2022 Jul 07;9:917610
pubmed: 35872892
Circulation. 2001 Jan 16;103(2):220-5
pubmed: 11208680
Circulation. 2001 Jul 3;104(1):39-45
pubmed: 11435335
Front Med (Lausanne). 2022 Mar 07;9:838564
pubmed: 35350578
Ann Thorac Surg. 1999 Dec;68(6):2177-80
pubmed: 10616998
J Geriatr Cardiol. 2018 Jul;15(7):517-518
pubmed: 30364743
J Invasive Cardiol. 2021 May;33(5):E387-E392
pubmed: 33893793
Circulation. 2020 Feb 11;141(6):e69-e92
pubmed: 31902242
N Engl J Med. 2022 Oct 20;387(16):1488-1500
pubmed: 36260793
Circ Heart Fail. 2020 Nov;13(11):e007405
pubmed: 33176455
Circulation. 2017 Aug 8;136(6):529-545
pubmed: 28576783
Circ Heart Fail. 2021 Nov;14(11):e008527
pubmed: 34706550
J Am Heart Assoc. 2022 Apr 5;11(7):e023713
pubmed: 35377180
Circulation. 2001 May 8;103(18):2254-9
pubmed: 11342473
Circ Cardiovasc Interv. 2018 Sep;11(9):e006930
pubmed: 30354593
J Thorac Dis. 2016 Jul;8(7):E495-502
pubmed: 27499982
Eur Heart J. 2005 Oct;26(20):2185-92
pubmed: 16014643
N Engl J Med. 2000 Nov 9;343(19):1388-98
pubmed: 11070105